Acumen Pharmaceuticals Inc
Research Acumen Pharmaceuticals Inc (ABOS) on Bullrun: market cap USD 154.75M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerABOS
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 154.75M
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 32.72M
- Free cash flow-USD 18.08M
Valuation Snapshot
latest market cap is USD 154.75M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 121.34M | -USD 115.63M | n/a | -2 | USD 53.99M | USD 31.16M | USD 70.43M |
| FY2024 | USD 0 | -USD 102.33M | -USD 86.23M | n/a | -1.71 | USD 35.63M | USD 29.42M | USD 181.82M |
| FY2023 | USD 0 | -USD 52.37M | -USD 43.09M | n/a | -1.08 | USD 66.89M | USD 29.90M | USD 266.97M |
| FY2022 | USD 0 | -USD 42.86M | -USD 35.31M | n/a | -1.06 | USD 130.10M | USD 0 | USD 188.78M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 154.75M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 127.81M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 103.36M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 222.38M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 221.00M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 273.60M | n/a | n/a | n/a |
About Acumen Pharmaceuticals Inc
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement with Halozyme, Inc.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Acumen Pharmaceuticals Inc's market cap?
Acumen Pharmaceuticals Inc's market capitalization is USD 154.75M.
What does Acumen Pharmaceuticals Inc do?
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug, as well as with JCR Pharmaceuticals Co.